Keyphrases
COVID-19
100%
Plant-produced
100%
Angiotensin-converting Enzyme 2 (ACE2)
100%
Recombinant
100%
Potential Therapeutics
100%
Plant Development
100%
Fc-fusion Protein
100%
Nicotiana Benthamiana
22%
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
22%
Host Cell
11%
Therapeutic Agents
11%
Causative Agents
11%
IC50 Value
11%
IC50
11%
Leaf Fresh Weight
11%
Entry Stage
11%
Post-infiltration
11%
Global Public Health
11%
Receptor-binding Domain
11%
Therapeutic Candidates
11%
Vero Cells
11%
Clinical Trials
11%
Fusion Protein
11%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
11%
Human Population
11%
Viral Infection
11%
In Vitro Activity
11%
Potential Threats
11%
Recombinant Fusion Proteins
11%
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
11%
Fc Region
11%
Entry Receptor
11%
Infectivity
11%
Cell Entry
11%
Commercial Use
11%
Human IgG1
11%
In Vitro Neutralization
11%
Human Coronavirus (HCoV)
11%
Pharmacology, Toxicology and Pharmaceutical Science
SARS Coronavirus
100%
Angiotensin Converting Enzyme 2
100%
Chimeric Protein
100%
Infection
18%
Receptor
18%
IC50
18%
Coronavirinae
9%
Nicotiana benthamiana
9%
Clinical Trial
9%
Virus Infection
9%
Immunoglobulin G1
9%
Coronaviridae
9%
Middle East Respiratory Syndrome Coronavirus
9%
Diseases
9%
Biochemistry, Genetics and Molecular Biology
Angiotensin-Converting Enzyme 2
100%
SARS Coronavirus
100%
Chimeric Protein
100%
IC50
18%
Nicotiana benthamiana
9%
Binding Domain
9%
Fresh Weight
9%
Coronavirinae
9%
Clinical Trial
9%
Coronaviridae
9%
Middle East Respiratory Syndrome Coronavirus
9%
Receptor Binding
9%